Early CTEPH Diagnosis Linked to Key Benefits, ‘Acceptable’ Costs

Early CTEPH Diagnosis Linked to Key Benefits, ‘Acceptable’ Costs

307589

Early CTEPH Diagnosis Linked to Key Benefits, ‘Acceptable’ Costs

Using a healthcare cost model, researchers in the Netherlands found that an early diagnosis of chronic thromboembolic pulmonary hypertension (CTEPH) leads to substantial life expectancy and quality of life benefits at an “acceptable” price. Although greater healthcare costs were associated with an earlier diagnosis — primarily due to the costs of medications — “according to Dutch health economic standards, additional costs remain below the deemed acceptable limit,” the researchers wrote. According to the team, these findings…

You must be logged in to read/download the full post.